Dianthus Therapeutics to Join Jefferies Global Healthcare Conference

NEW YORK and WALTHAM, Mass., May 30, 2024 – Dianthus Therapeutics, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker DNTH, has announced its participation in the upcoming Jefferies Global Healthcare Conference. Marino Garcia, the Chief Executive Officer of Dianthus Therapeutics, is scheduled to deliver a corporate presentation on June 6, 2024, at 1:30 p.m. Eastern Time in New York. Interested parties can access a live webcast of this presentation through the "News and Events" page in the Investors section of the Dianthus Therapeutics website.

Dianthus Therapeutics Overview

Dianthus Therapeutics is a clinical-stage biotechnology firm focused on the development of cutting-edge antibody complement therapies designed to treat severe autoimmune and inflammatory diseases. The company operates out of New York City and Waltham, Mass., and boasts a team comprising seasoned executives from the biotech and pharmaceutical sectors. Their mission is to develop innovative medicines that significantly improve the lives of individuals suffering from serious health conditions.

Dianthus Therapeutics has embarked on a Phase 2 clinical trial for DNTH103, an investigational C1s inhibitor. This trial is targeted at treating generalized Myasthenia Gravis. Additionally, the company plans to launch further Phase 2 trials in 2024 to explore the efficacy of DNTH103 in treating other neuromuscular disorders such as Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!